J Korean Soc Transplant.  2011 Mar;25(1):8-14. 10.4285/jkstn.2011.25.1.8.

Management of Posttransplantation Diabetes Mellitus (PTDM)

• Cha BS
• Moon JH

• KMID: 2202343
• DOI: http://doi.org/10.4285/jkstn.2011.25.1.8

Abstract

New-onset diabetes after transplantation (NODAT) is a common complication of solid-organ transplantation. As long-term posttransplant survival continues to improve, increasing attention has been placed on NODAT. Because NODAT is a potent predictor of graft failure and cardiovascular mortality in the transplant population, early detection and management of NODAT are important issues. The risk factors for NODAT in transplant recipients include older age, obesity, family history, hepatitis C virus infection, and immunosuppressive agents, such as corticosteroids and calcineurin inhibitors. Management of NODAT must be considered at the pretransplantation stage to screen high risk patients and prevent NODAT. Although NODAT management is similar to type 2 diabetes management in the general population, there are some specific considerations in NODAT management, including the immunosuppressive agent. Further studies are needed to suggest optimal management guidelines for NODAT.

Keyword

Diabetes mellitus; Organ transplantation; Risk factors; Postoperative complications; Diagnosis; Treatment outcome

MeSH Terms

Adrenal Cortex Hormones
Calcineurin
Diabetes Mellitus
Hepacivirus
Humans
Immunosuppressive Agents
Obesity
Organ Transplantation
Postoperative Complications
Risk Factors
Transplants
Treatment Outcome
Adrenal Cortex Hormones
Calcineurin
Immunosuppressive Agents

Reference

References

1). Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003; 3:178–85.

2). Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl. 2004; 10:349–55.

3). Benhamou PY, Penfornis A. Natural history, prognosis, and management of transplantation-induced diabetes mellitus. Diabetes Metab. 2002; 28:166–75.

4). Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrøm J, Leivestad T, Egeland T, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997; 64:979–83.

5). Olefsky JM, Kimmerling G. Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci. 1976; 271:202–10.

6). Weir MR, Fink JC. Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis. 1999; 34:1–13.

7). Hjelmesaeth J, Hartmann A, Kofstad J, Egeland T, Stenstrøm J, Fauchald P. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant. 2001; 16:829–35.

8). Hricik DE, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation. 1991; 51:374–7.

9). Hollander AA, Hene RJ, Hermans J, van Es LA, van der Woude FJ. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol. 1997; 8:294–301.

10). Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and metaanalysis. Am J Transplant. 2004; 4:583–95.

11). Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, van Veldhuisen P. Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, place-bo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus longterm, low-dose corticosteroid therapy. Ann Surg. 2008; 248:564–77. Erratum in: Am J Transplant 2008;8: 1080.

12). Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008; 8:307–16.

13). Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, et al. CARMEN Study Group. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation. 2005; 79:807–14.

14). Yagisawa T, Takahashi K, Teraoka S, Toma H, Agishi T, Ota K. Effects of cyclosporine on glucose metabolism in kidney transplant recipients and rats. Transplant Proc. 1987; 19:1801–3.

15). Hahn HJ, Dunger A, Laube F, Besch W, Radloff E, Kauert C, et al. Reversibility of the acute toxic effect of cyclosporin A on pancreatic B cells of Wistar rats. Diabetologia. 1986; 29:489–94.

16). Garvin PJ, Niehoff M, Staggenborg J. Cyclosporine's effect on canine pancreatic endocrine function. Transplantation. 1988; 45:1027–31.

17). Yale JF, Chamelian M, Courchesne S, Vigeant C. Peripheral insulin resistance and decreased insulin secretion after cyclosporine A treatment. Transplant Proc. 1988; 20(3 Suppl 3):985–8.

18). Strasser S, Alejandro R, Shapiro ET, Ricordi C, Todo S, Mintz DH. Effect of FK506 on insulin secretion in normal dogs. Metabolism. 1992; 41:64–7.

19). Tamura K, Fujimura T, Tsutsumi T, Nakamura K, Ogawa T, Atumaru C, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation. 1995; 59:1606–13.

20). van Hooff JP, van Duijnhoven EM, Christiaans MH. Tacrolimus and glucose metabolism. Transplant Proc. 1999; 31:49S–50S.

21). Maes BD, Kuypers D, Messiaen T, Evenepoel P, Mathieu C, Coosemans W, et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation. 2001; 72:1655–61.

22). Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, et al. Incidence and cost of new onset diabetes mellitus among U.S. waitlisted and transplanted renal allograft recipients. Am J Transplant. 2003; 3:590–8.

23). Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, et al. DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007; 7:1506–14. Erratum in: Am J Transplant 2008;8: 1. Am J Transplant 2008;8: 908. Dosage error in article text.

24). European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 1994; 344:423–8.

25). Grimm M, Rinaldi M, Yonan NA, Arpesella G, Arizón del Prado JM, Pulpón LA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial. Am J Transplant. 2006; 6:1387–97.

26). Sumrani NB, Delaney V, Ding ZK, Davis R, Daskalakis P, Friedman EA, et al. Diabetes mellitus after renal transplantation in the cyclosporine era-an analysis of risk factors. Transplantation. 1991; 51:343–7.

27). Al-Uzri A, Stablein DM, A Cohn R. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation. 2001; 72:1020–4.

28). Greenspan LC, Gitelman SE, Leung MA, Glidden DV, Mathias RS. Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis. Pediatr Nephrol. 2002; 17:1–5.

29). Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation. 1998; 65:515–23.

30). Williams JJ, Lund LH, LaManca J, Kunavarapu C, Cohen DJ, Heshka S, et al. Excessive weight gain in cardiac transplant recipients. J Heart Lung Transplant. 2006; 25:36–41.

31). Armstrong KA, Campbell SB, Hawley CM, Nicol DL, Johnson DW, Isbel NM. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant. 2005; 5:2710–8.

32). Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Posttransplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 2001; 59:732–7.

33). Marrero D, Hernandez D, Tamajón LP, Rivero M, Lampreabe I, Checa MD, et al. For the Spanish Late Allograft Dysfunction Study Group. Pre-transplant weight but not weight gain is associated with new-onset diabetes after transplantation: a multicentre cohort Spanish study. NDT Plus. 2010; 3(Suppl 2):ii15–ii20.

34). Grimbert S, Valensi P, Lévy-Marchal C, Perret G, Richardet JP, Raffoux C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol. 1996; 20:544–8.

35). Gürsoy M, Güvener N, Köksal R, Karavelioğ lu D, Baysal C, Ozdemir N, et al. Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. Transplant Proc. 2000; 32:561–2.

36). Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002; 13:1374–80.

37). Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation. 2001; 72:1066–72.

38). Konrad T, Vicini P, Zeuzem S, Toffolo G, Briem D, Lormann J, et al. Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease. Exp Clin Endocrinol Diabetes. 1999; 107:343–9.

39). Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol. 2003; 14:2092–8.

40). Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009; 49:739–44.

41). Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Posttransplant diabetes mellitus and HCV seropositive status after renal transplantation: metaanalysis of clinical studies. Am J Transplant. 2005; 5:2433–40.

42). Hjelmesaeth J, Sagedal S, Hartmann A, Rollag H, Egeland T, Hagen M, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-on-set diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia. 2004; 47:1550–6.

43). Hjelmesaeth J, Müller F, Jenssen T, Rollag H, Sagedal S, Hartmann A. Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage. Nephrol Dial Transplant. 2005; 20:2311–5.

44). Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005; 19:291–8.

45). Joss N, Staatz CE, Thomson AH, Jardine AG. Predictors of new onset diabetes after renal transplantation. Clin Transplant. 2007; 21:136–43.

46). Iida S, Ishida H, Tokumoto T, Omoto K, Shirakawa H, Shimizu T, et al. New-onset diabetes after transplantation in tacrolimus-treated, living kidney transplantation: long-term impact and utility of the pretransplant OGTT. Int Urol Nephrol. 2010; 42:935–45.

47). Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, et al. American Society of Transplantation. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant. 2001; 1(Suppl 2):3–95.

48). Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, et al. International Expert Panel. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003; 75(10 Suppl):SS3–24.

49). Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003; 26(Suppl 1):S5–20.

50). American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management-2000 update. Endocr Pract. 2000; 6:43–84.

51). Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation. 2008; 85:353–8.

52). Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet. 1996; 31:111–9.

53). Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther. 2005; 78:388–99.

54). Villanueva G, Baldwin D. Rosiglitazone therapy of post-transplant diabetes mellitus. Transplantation. 2005; 80:1402–5.

55). Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant. 2004; 4:2135–8.

56). Säemann MD, Krebs M. Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) – A new therapeutic option? Wien Klin Wochens chr. 2010; 122:198–202.

57). Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Dilzer S, et al. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol. 2007; 47:165–74.

58). American Diabetes Association. Summary of revisions to the 2011 clinical practice recommendations. Diabetes Care. 2011; 34(Suppl 1):S3.